Zomedica Corp.

ZOM

CA98980M1095

Healthcare Facilities & Services

Market Closed - Nyse Other stock markets 04:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
0.1843 ^USD	+8.92%		+15.98%	-7.94%

May. 15	Zomedica Corp. Releases Over-The-Air Software Update Capabilities for Its Truforma(R) Platform	CI
May. 09	Earnings Flash (ZOM) ZOMEDICA Posts Q1 Revenue $6.3M	MT

Zomedica Pharmaceuticals Corp. Approves Board Appointments

September 25, 2020 at 11:00 am EDT

Zomedica Pharmaceuticals Corp. at its Annual and Special Meeting of Shareholders, approved the appointment of Robert Cohen and Christopher Wolfenberg as directors of the company.

Latest news about Zomedica Corp.

Zomedica Corp. Releases Over-The-Air Software Update Capabilities for Its Truforma(R) Platform	May. 15	CI
Earnings Flash (ZOM) ZOMEDICA Posts Q1 Revenue $6.3M	May. 09	MT
Transcript : Zomedica Corp., Q1 2024 Earnings Call, May 09, 2024	May. 09
Zomedica Corp. Provides Revenue Guidance for Full Year 2024	May. 09	CI
Zomedica Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Zomedica Seeks Acquisitions	Apr. 01	CI
Transcript : Zomedica Corp., Q4 2023 Earnings Call, Apr 01, 2024	Apr. 01
Earnings Flash (ZOM) ZOMEDICA Posts Q4 Revenue $7.3M	Apr. 01	MT
Zomedica Corp. Reiterates Revenue Guidance for Full Year 2024	Apr. 01	CI
Zomedica Corp. Announces Publication of Research Con Including TRUFORMA(R) Platform Is More Accurate Diagnostic Test for Feline Hyperthyroidism Than Chemiluminescent Immunoassay Platform	Mar. 14	CI
Transcript : Zomedica Corp. - Shareholder/Analyst Call	Feb. 28
Transcript : Zomedica Corp. - Analyst/Investor Day	Feb. 13
Zomedica Pharmaceuticals Reports Preliminary Q4 Revenue	Jan. 17	MT
Transcript : Zomedica Corp., 2023 Sales/ Trading Statement Call, Jan 17, 2024	Jan. 17
Zomedica Corp. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 and Full Year 2024	Jan. 17	CI
Zomedica Corp. Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of Three New Assays for Commonly Performed Diagnostic Tests for Canine Gastrointestinal Disease	Dec. 18	CI
Zomedica Announces Presentation of Clinical Data in Support of New Indications for Pulsevet Shock Wave Therapy	Dec. 06	CI
Earnings Flash (ZOM) ZOMEDICA Posts Q3 Revenue $6.3M	Nov. 13	MT
Transcript : Zomedica Corp., Q3 2023 Earnings Call, Nov 13, 2023	Nov. 13
Zomedica Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Zomedica Corp. acquired Qorvo Biotechnologies, LLC from Qorvo US, Inc. for $11.3 million.	23-10-04	CI
Zomedica Corp. Launches its Newest Assay - Endogenous ACTH	23-09-14	CI
Zomedica Pharmaceuticals Issued Warning From NYSE American For Failing to Meet Listing Requirement	23-09-13	MT
Zomedica Completes Acquisition of Structured Monitoring Products	23-09-05	MT
Earnings Flash (ZOM) ZOMEDICA Posts Q2 Revenue $6M	23-08-10	MT

Zomedica Corp. is a veterinary health company. The Company is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The Company's product portfolio includes diagnostics and medical devices that emphasize patient health and practice health. Its Diagnostics segment consists of TRUFORMA, VetGuardian, and TRUVIEW products. Its Therapeutic Devices segment consists of Assisi and PulseVet products. Its TRUFORMA platform comprises point-of-care diagnostic products for disease states in dogs, cats and horses, providing assays for use at the point-of-care that provide reference lab accuracy. Its TRUVIEW platform consists of the TRUVIEW digital cystoscopy instrument providing microscopic images and related pathology services which enable practitioners to receive a pathologist interpretation of the images. The Assisi Loop platform includes a series of products that use targeted pulsed electromagnetic field (tPEMF) therapy.

Sector

Healthcare Facilities & Services

Calendar

2024-05-16 - Fetch dvm360® Conference

More about the company